The earnings call highlighted significant progress in DiaMedica's ongoing clinical programs, particularly in preeclampsia and stroke, alongside successful capital raising and strategic additions to the team and market indices. However, the company faces financial challenges with increased net losses and rising operational expenses.

Company Guidance -

Q3 2025

During DiaMedica Therapeutics' Q2 2025 earnings call, significant progress was highlighted in their preeclampsia program, particularly with the recombinant KLK1 protein candidate, DM199. Interim results from Part 1a of a Phase II trial showed statistically significant reductions in systolic and diastolic blood pressure, improved uterine artery blood flow, and enhanced placental perfusion. The trial is advancing to Cohort 10, with plans to enroll three concurrent cohorts addressing preeclampsia and fetal growth restriction. The company also completed a $30 million private placement to extend its cash runway into 2027, supporting ongoing trials for both stroke and preeclampsia programs. Financially, DiaMedica reported a net loss of $15.4 million for the first half of 2025, with R&D expenses rising to $11.5 million due to trial expansions. The call also noted progress in the ReMEDy2 stroke trial, with enrollment tracking above 25% and an expected interim analysis in Q2 2026.

Positive Interim Results for Preeclampsia Program

Announced positive interim results from Part 1a of the Phase II trial of DM199 for preeclampsia, showing statistically significant reduction in systolic and diastolic blood pressure without placental transfer, indicating potential efficacy and safety.

Advancement in Stroke Program

Presented at the European Stroke Organization Conference with promising results from the ReMEDy1 Phase II trial. Enrollment for the ongoing ReMEDy2 trial is progressing well, with an expected interim analysis in Q2 2026.

Successful $30 Million Private Placement

Completed a $30 million private placement, extending the cash runway into the second half of 2027, allowing further development of stroke and preeclampsia programs.

Addition to Russell 2000 and Russell 3000 Indexes

DiaMedica was added to these indexes, enhancing visibility among institutional investors.

Appointment of Dr. Julie Krop as Chief Medical Officer

Dr. Krop, with extensive experience in biopharma, joined DiaMedica, bringing expertise in the development of treatments for severe preeclampsia.

Diamedica Therapeutics (DMAC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DMAC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.16 / -	-0.15	―	―	―
Aug 12, 2025	2025 (Q2)	-0.19 / -0.18	-0.13	-38.46% (-0.05)	―
May 13, 2025	2025 (Q1)	-0.18 / -0.18	-0.14	-28.57% (-0.04)	―
Mar 17, 2025	2024 (Q4)	-0.17 / -0.18	-0.12	-50.00% (-0.06)	―
Nov 13, 2024	2024 (Q3)	-0.15 / -0.15	-0.12	-25.00% (-0.03)	―
Aug 07, 2024	2024 (Q2)	-0.16 / -0.13	-0.16	18.75% (+0.03)	―
May 08, 2024	2024 (Q1)	-0.16 / -0.14	-0.2	30.00% (+0.06)	―
Mar 19, 2024	2023 (Q4)	-0.14 / -0.12	-0.14	14.29% (+0.02)	―
Nov 13, 2023	2023 (Q3)	-0.13 / -0.12	-0.12	0.00% (0.00)	―
Aug 14, 2023	2023 (Q2)	-0.18 / -0.16	-0.13	-23.08% (-0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DMAC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$5.22	$6.00	+14.94%
May 13, 2025	$3.98	$4.00	+0.50%
Mar 17, 2025	$5.99	$5.21	-13.02%
Nov 13, 2024	$4.26	$4.12	-3.29%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Diamedica Therapeutics Inc (DMAC) report earnings?

Diamedica Therapeutics Inc (DMAC) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is Diamedica Therapeutics Inc (DMAC) earnings time?

Diamedica Therapeutics Inc (DMAC) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DMAC EPS forecast?

DMAC EPS forecast for the fiscal quarter 2025 (Q3) is -0.16.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing